touchPANEL DISCUSSION Unlocking the pathogenesis of chronic spontaneous urticaria to inform the future treatment landscape
Leading experts explain how recent advances in our understanding of the pathogenesis of chronic spontaneous urticaria is guiding emerging targeted therapies, and consider how they may refine future management to reduce its impact on patient quality of life.
Prof. Dr med. Marcus Maurer
Charité University Medicine, Berlin, Germany
CHAIR
Panelists:
Introduction
Prof. Dr med. Marcus Maurer introduces the faculty and topics for discussion on the diagnosis and management of CSU.
view bio and disclosures 1/4 Next ChapterDiagnosing CSU: Reducing the impact on patients
The panel considers the burden of CSU and the importance of making a differential diagnosis, and reflects on how best to measure disease severity and impact on the patient’s quality of life and function.
view bio and disclosures 2/4 Next ChapterWhat lies beneath: The pathogenesis of CSU
The panel explores recent scientific advances in our understanding of CSU pathogenesis, and discusses the potential implications of emerging endotypes for the development of novel treatments that target underlying disease mechanisms.
view bio and disclosures 3/4 Next ChapterCSU treatment landscape: Current recommendations and future therapies
After appraising the latest guidelines and available treatments, the panel considers how emerging agents currently in clinical development may inform future patient management approaches.
view bio and disclosures 4/4 Take CE/CME TestOverview & Learning Objectives
Overview
In this activity, the expert panel discusses the burden of disease and how recent advances in our understanding of the pathogenesis of chronic spontaneous urticaria may help to inform future treatment approaches for improved control of symptoms.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of immunologists, allergists and dermatologists involved in the management of chronic spontaneous urticaria.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Prof. Dr med. Marcus Maurer discloses: Speaker/advisor for and/or has received research funding from Allakos, Allerdia, Amgen, Aralez Bio, Argenx, AstraZeneca, Celldex Therapeutics, Centogene, CSL Behring, FAES Farma, Genentech, GI Innovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie Pharmaceutical, Novartis, Pfizer, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB and Uriach.
Dr Melinda Gooderham discloses: Â Advisory board/panel fees from AbbVie Inc., Amgen, AnaptysBio, Arcutis Pharmaceuticals Inc., Asana BioSciences, Aslan Pharmaceuticals, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Galderma SA., Janssen Inc., Leo Pharma, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals and UCB. Consultant fees from AbbVie Inc., Akros Pharma Inc., Amgen, AnaptysBio, Aslan Pharmaceuticals, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Incyte, Janssen Inc., Kyowa Kirin, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals and UCB. Grants/research support from AbbVie Inc., Akros Pharma Inc., Amgen, AnaptysBio, Arcutis Pharmaceuticals Inc., Asana BioSciences, Bausch Health, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Celgene Corporation, Coherus Biosciences, DermiraInc., Eli Lilly and Company, Galderma SA., GlaxoSmithKline, Incyte, Janssen Inc., Kyowa Kirin, Leo Pharma, MedImmune, Merck and Co., Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Laboratories, Sanofi Genzyme, Sun Pharmaceuticals, Takeda Pharmaceuticals and UCB.
Prof. David Khan has no interests/relationships or affiliations to disclose in relation to this activity.
Content reviewer
Ann Lin, DO has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 11 April 2022. Date credits expire: 11 April 2023.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
Learning Objectives
After watching this activity, participants should be better able to:
- Recognize the burden of disease of chronic spontaneous urticaria (CSU) and the importance of a differential diagnosis
- Describe the underlying pathogenesis of CSU and how it can inform the development of future treatments
- Recall the current treatment recommendations for CSU and evaluate potential new treatments in development
Faculty & Disclosures
Prof. Dr med. Marcus Maurer
Charité University Medicine, Berlin, Germany
Marcus Maurer, MD, is Professor of Dermatology and Allergy at the Charité University Medicine in Berlin, Germany. read more
Prof. Maurer is also Co-Director of the Fraunhofer Site for Allergology and Immunology at the Fraunhofer Translational Medicine and Pharmacology ITMP, and Executive Director for the Institute of Allergology at Charité University Medicine.Â
A leading expert in the fields of allergy and dermatology, Prof. Maurer is a coordinator of the Global Allergy and Asthma European Networks (GA²LEN) and Centres of Reference and Excellence for urticaria (UCARE) and angioedema (ACARE).
His areas of clinical interest include urticaria, angioedema, mastocytosis, pruritus, skin infections and allergic diseases. Active in research, Prof. Maurer’s work focuses on mast cell biology, neuroimmunology, inflammation, innate immunity and tolerance. He has supervised more than 60 clinical trials (phases I through IV), contributed to over 650 publications in peer-reviewed journals, alongside 45 books and book chapters.
Prof. Dr med. Marcus Maurer discloses: Speaker/advisor for and/or has received research funding from Allakos, Allerdia, Amgen, Aralez Bio, Argenx, AstraZeneca, Celldex Therapeutics, Centogene, CSL Behring, FAES Farma, Genentech, GI Innovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie Pharmaceutical, Novartis, Pfizer, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB and Uriach.
Dr Melinda Gooderham
SKiN Centre for Dermatology, Ontario, Canada
Melinda Gooderham, MSc, MD, FRCPC, is Consultant Dermatologist and Medical Director at the SKiN Centre for Dermatology in Ontario, Canada. read more
Dr Gooderham is also an Assistant Professor at Queen’s University, a Consultant Physician at the Peterborough Regional Health Centre, and an Investigator with Probity Medical Research, Canada. She is a fellow of the Royal College of Physicians and Surgeons of Canada.
Dr Gooderham is actively involved in teaching medical students, residents, nurse practitioners and physicians, with both didactic and clinical hands-on teaching. Her clinical practice focuses on psoriasis, atopic dermatitis, skin cancer and clinical research. As an author and reviewer, Dr Gooderham contributes to peer-reviewed publications in the field of dermatology.
Dr Melinda Gooderham discloses: Advisory board/panel fees from AbbVie Inc., Amgen, AnaptysBio, Arcutis Pharmaceuticals Inc., Asana BioSciences, Aslan Pharmaceuticals, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Galderma SA., Janssen Inc., Leo Pharma, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals and UCB. Consultant fees from AbbVie Inc., Akros Pharma Inc., Amgen, AnaptysBio, Aslan Pharmaceuticals, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Incyte, Janssen Inc., Kyowa Kirin, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals and UCB. Grants/research support from AbbVie Inc., Akros Pharma Inc., Amgen, AnaptysBio, Arcutis Pharmaceuticals Inc., Asana BioSciences, Bausch Health, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Celgene Corporation, Coherus Biosciences, DermiraInc., Eli Lilly and Company, Galderma SA., GlaxoSmithKline, Incyte, Janssen Inc., Kyowa Kirin, Leo Pharma, MedImmune, Merck and Co., Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Laboratories, Sanofi Genzyme, Sun Pharmaceuticals, Takeda Pharmaceuticals and UCB.
Prof. David Khan
Southwestern Medical Center, University of Texas, USA
David Khan, MD, is Professor of Internal Medicine and Pediatrics at the University of Texas Southwestern Medical Center in Dallas, Texas, USA, where he has been Program Director for the Allergy & Immunology fellowship programme since 1998. read more
Prof. Khan is the current president of the American Academy of Allergy, Asthma, and Immunology (AAAAI); is a past president of the Texas Allergy, Asthma and Immunology Society; and was formerly a member of the Joint Task Force on Practice Parameters for Allergy & Immunology.
His research interests include refractory chronic urticaria, drug allergy and mood disorders in asthma.
Prof. David Khan has no interests/relationships or affiliations to disclose in relation to this activity.
Register to touchIMMUNOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
